Adjunctive Use of Benzoyl Peroxide 10 % in Mild Hidradenitis Suppurativa

Guideline Recommendations

• The American Academy of Dermatology (AAD) Clinical Management Guidelines do not list benzoyl peroxide as a standalone therapy for hidradenitis suppurativa (HS); it is endorsed only as an adjunctive skin cleanser, based on expert opinion, alongside agents such as chlorhexidine and zinc pyrithione. 1
• In patients with mild HS (Hurley Stage I) receiving topical clindamycin 1 %, adding benzoyl peroxide 10 % can help reduce the risk of Staphylococcus aureus resistance that may develop with clindamycin monotherapy. 1

Evidence Quality and Limitations

• No randomized controlled trials or case series have directly evaluated benzoyl peroxide for HS lesions; the evidence base is therefore very weak. 1
• The recommendation to use benzoyl peroxide in HS is extrapolated from acne vulgaris studies, which demonstrated that benzoyl peroxide prevents antibiotic resistance when combined with topical antibiotics. This indirect evidence is low‑quality for HS. 2
• The AAD guidelines classify the use of benzoyl peroxide in HS as expert opinion rather than being supported by clinical trial data. 1

Clinical Application (Adjunctive Use)

• Benzoyl peroxide 10 % may be applied as a wash to all affected intertriginous areas only when combined with topical clindamycin 1 % (twice daily for 12 weeks) in Hurley Stage I disease. (The wash recommendation is derived from guideline expert opinion.) 1
• Benzoyl peroxide should never be used as monotherapy for HS; its role is limited to reducing antibiotic resistance when used alongside clindamycin. 1

Contra‑indications and Limitations

• For Hurley Stage II or III disease (recurrent abscesses, sinus tracts, or scarring), systemic antibiotics (e.g., clindamycin + rifampicin) or biologic therapy (e.g., adalimumab) are required; benzoyl peroxide is inappropriate. 1
• Benzoyl peroxide has no demonstrated effect on deep inflammatory nodules or abscesses that characterize HS. 1

First‑Line Therapies Recommended by AAD Guidelines

• Mild disease (Hurley I): Topical clindamycin 1 % applied twice daily for 12 weeks. 1
• Moderate disease (Hurley II): Oral clindamycin 300 mg twice daily plus rifampicin 300–600 mg daily for 10–12 weeks, achieving a 71–93 % clinical response rate. 1
• Severe disease (Hurley III): Adalimumab dosing regimen—160 mg week 0, 80 mg week 2, then 40 mg weekly from week 4 onward. 1

Common Pitfall

• Treating HS as if it were acne vulgaris is the most frequent error; while benzoyl peroxide is highly effective for acne, HS is a chronic inflammatory follicular disease that requires systemic anti‑inflammatory therapy rather than topical antimicrobials alone. 1

Hidradenitis Suppurativa Treatment Guidelines

Introduction to Hidradenitis Suppurativa Treatment

• The Infectious Diseases Society of America (IDSA) guidelines distinguish hidradenitis suppurativa from simple recurrent abscesses, noting that the treatment approach differs fundamentally 3, 4

Treatment Recommendations

• The IDSA guidelines state that eradication of the underlying cause can be curative, referring to treating the hidradenitis suppurativa itself, not using mupirocin 3
• A randomized trial showed that twice-daily intranasal mupirocin for 5 days did not reduce the frequency of subsequent skin infections in MRSA carriers 3, 4
• The benefits of adjunctive antimicrobial therapy, including mupirocin, in preventing recurrences are unknown 3, 4
• Mupirocin is a topical decolonization agent for nasal MRSA carriage, not a treatment for the chronic inflammatory disease process of hidradenitis suppurativa 3, 4
• For mild HS (Hurley Stage I), topical clindamycin 1% solution/gel twice daily for 12 weeks is the first-line therapy 5, 6
• Consider combining topical clindamycin with benzoyl peroxide to reduce Staphylococcus aureus resistance risk 5
• Intralesional triamcinolone (10 mg/mL) can be used for inflamed lesions 5, 6
• For moderate HS (Hurley Stage II), first-line treatment is tetracycline 500 mg twice daily for up to 4 months or doxycycline 100 mg once or twice daily 5, 6
• Second-line treatment for moderate HS is clindamycin 300 mg twice daily plus rifampicin 300-600 mg daily for 10-12 weeks 5, 6
• For severe HS (Hurley Stage III), adalimumab can be initiated with 160 mg at week 0, 80 mg at week 2, then 40 mg weekly starting at week 4 5, 6
• Surgical intervention is often necessary for definitive treatment of severe HS 5, 7

Treatment Algorithm

• Assess Hurley stage to determine disease severity 5, 6
• Mild disease: start topical clindamycin 5, 6
• Moderate disease: start oral tetracyclines, escalate to clindamycin/rifampicin if needed 5, 6
• Severe disease: initiate adalimumab and refer to HS surgical multidisciplinary team 5, 7
• Monitor response at 12 weeks using HiSCR (Hidradenitis Suppurativa Clinical Response) 5, 6

Additional Management Considerations

• Encourage smoking cessation, as tobacco is associated with worse outcomes 5, 6
• Promote weight loss in patients with obesity 5, 6
• Screen for depression/anxiety and cardiovascular risk factors 5, 7
• Provide appropriate wound care for draining lesions 5, 6
• Consider treatment breaks after antibiotic courses to limit antimicrobial resistance 5